Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact

Journal of Bone and Mineral Research

Volumn 25, Issue 9, 2010, Pages 2051-2058

  Elis, Sebastien ^a   Courtland, Hayden William ^a   Wu, Yingjie ^a   Fritton, J Christopher ^a   Sun, Hui ^a   Rosen, Clifford J ^b   Yakar, Shoshana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

Bone; Endocrine IGF 1; IGF 1; IGF1KO; Intermittent PTH; Micro Computed Tomography; Transgenic Mice

Indexed keywords

OSTEOCALCIN; PARATHYROID HORMONE; SOMATOMEDIN C;

ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; BONE GROWTH; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FEMUR; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SKELETON; THICKNESS; TRABECULAR BONE; TRANSGENE;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; PARATHYROID HORMONE;

EID: 77956832787     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.100     Document Type: Article

References (34)

1. Yakar S, Canalis E, Sun H, et al. Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions. J Bone Miner Res. 2009;24:1481-1492.
2. Sebastien Elis H-WC, Wu Y, Rosen CJ, et al. Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties, even in the absence of tissue IGF-1. J Bone Miner Res. 2010;25:1257-1266.
3. Poole KE, Reeve J. Parathyroid hormone: a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005;5:612-617.
4. Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, Sims NA. Mechanisms involved in skeletal anabolic therapies. Ann NY Acad Sci. 2006;1068:458-470.
5. Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor 1 is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002;17:1570-1578.
6. Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest. 1989;83:60-65. (Pubitemid 19048405)
7. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001;142:4349-4356.
8. Pfeilschifter J, Laukhuf F, Muller-Beckmann B, Blum WF, Pfister T, Ziegler R. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J Clin Invest. 1995;96:767-774.
9. Watson P, Lazowski D, Han V, Fraher L, Steer B, Hodsman A. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone. 1995;16:357-365.
10. Wang Y, Nishida S, Boudignon BM, Burghardt A, Elalieh HZ, Hamilton MM, Majumdar S, Halloran BP, Clemens TL, Bikle DD. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res. 2007;22:1329-1337.
11. Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int. 2007;18:973-979. (Pubitemid 46889557)
12. Wu Y, Sun H, Yakar S, Leroith D. Elevated levels of IGF-1 in serum rescue the severe growth retardation of IGF-1 null mice. Endocrinology. 2009;150:4395-4403.
13. Yakar S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair Y, Leroith D, Rosen CJ. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol. 2006;189:289-299.
14. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110:771-781.
15. Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113:96-105.
16. Jepsen KJ, Hu B, Tommasini SM, Courtland HW, Price C, Terranova CJ, Nadeau JH. Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility. Mamm Genome. 2007;18:492-507. (Pubitemid 47360414)
17. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
18. Wu Y, Sun H, Yakar S, LeRoith D. Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology. 2009;150:4395-4403.
19. Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone. 2007;40:391-398.
20. Bianda T, Glatz Y, Bouillon R, Froesch ER, Schmid C. Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults. J Clin Endocrinol Metab. 1998;83:81-87.
21. Menaa C, Vrtovsnik F, Friedlander G, Corvol M, Garabedian M. Insulin-like growth factor I, a unique calcium-dependent stimulator of 1,25-dihydroxyvitamin D3 production. Studies in cultured mouse kidney cells. J Biol Chem. 1995;270:25461-25467.
22. Nesbitt T, Drezner MK. Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity. Endocrinology. 1993; 132:133-138.
23. Wong MS, Sriussadaporn S, Tembe VA, Favus MJ. Insulin-like growth factor I increases renal 1,25(OH)2D3 biosynthesis during low-P diet in adult rats. Am J Physiol. 1997;272:F698-703.
24. Wong MS, Tembe VA, Favus MJ. Insulin-like growth factor-I stimulates renal 1, 25- dihydroxycholecalciferol synthesis in old rats fed a low calcium diet. J Nutr. 2000;130:1147-1152.
25. Zoidis E, Gosteli-Peter M, Ghirlanda-Keller C, Meinel L, Zapf J, Schmid C. IGF-I and GH stimulate Phex mRNA expression in lungs and bones and 1,25-dihydroxyvitamin D(3) production in hypophysectomized rats. Eur J Endocrinol. 2002;146:97-105.
26. Sato K. [Therapeutic agents for disorders of bone and calcium metabolism. Development of nasal formulation of hPTH (1-34)]. Clin Calcium. 2007;17:64-71.
27. Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone. 2007;40:1447-1452. (Pubitemid 46756408)
28. Thomas T. Intermittent parathyroid hormone therapy to increase bone formation. Joint Bone Spine. 2006;73:262-269.
29. Rosen CJ. The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr. 2003;13:25-38.
30. Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC, Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene. 2002;282:1-17.
31. Yamaguchi M, Ogata N, Shinoda Y, Akune T, Kamekura S, Terauchi Y, Kadowaki T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology. 2005;146:2620-2628.
32. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology. 2008;149:2051-2061. (Pubitemid 351574504)
33. Amin S, Riggs BL, Melton LJ 3rd, Achenbach SJ, Atkinson EJ, Khosla S. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res. 2007;22:799-807.
34. Conover CA, Johnstone EW, Turner RT, Evans GL, John Ballard FJ, Doran PM, Khosla S. Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm IGF Res. 2002;12:178-183.